BMO Capital analyst Sean Dodge upgraded Icon (ICLR) to Outperform from Market Perform with a price target of $130, up from $100. The firm’s recent analysis indicates continued improvements in Icon’s large pharma backdrop. In additions, the shares are trading at a multi-decade low valuation, the analyst tells investors in a research note. BMO believes current share levels overly discount the risks from Icon’s accounting review and longer-term AI fears overhanging the space. It sees current levels as an attractive entry point.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICLR:
- Icon, Advarra enter partnership, introduces ‘research-ready’ site network model
- ICON plc options imply 2.8% move in share price post-earnings
- Icon price target lowered to $120 from $200 at Citi
- ICON plc options imply 4.1% move in share price post-earnings
- Icon price target lowered to $120 from $200 at Barclays